These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 30086795

  • 1. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L.
    Arthritis Res Ther; 2018 Aug 07; 20(1):171. PubMed ID: 30086795
    [Abstract] [Full Text] [Related]

  • 2. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.
    Ann Rheum Dis; 2015 Mar 07; 74(3):480-9. PubMed ID: 25561362
    [Abstract] [Full Text] [Related]

  • 3. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž, Tomšič M, Praprotnik S, Slovenian Rheumatologists.
    Clin Rheumatol; 2019 Feb 07; 38(2):297-305. PubMed ID: 30324406
    [Abstract] [Full Text] [Related]

  • 4. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R, Govoni M, Ding Q, Black CM, Kachroo S, Fan T, Ogbonnaya A, Donga P, Hill J, Makin C.
    Rheumatol Int; 2016 Jan 07; 36(1):143-53. PubMed ID: 26314368
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K, Flouri I, Repa A, Fragiadaki K, Sfikakis PP, Koutsianas C, Kaltsonoudis E, Voulgari PV, Drosos AA, Petrikkou E, Sidiropoulos P, Vassilopoulos D.
    Clin Exp Rheumatol; 2018 Jan 07; 36(2):254-262. PubMed ID: 29148406
    [Abstract] [Full Text] [Related]

  • 7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 07; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 9. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.
    Semin Arthritis Rheum; 2017 Oct 15; 47(2):183-192. PubMed ID: 28413099
    [Abstract] [Full Text] [Related]

  • 10. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J.
    Arthritis Rheumatol; 2014 May 15; 66(5):1282-90. PubMed ID: 24782185
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 15; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 13. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study.
    Meng H, Lam SH, So H, Tam LS.
    Semin Arthritis Rheum; 2024 Apr 15; 65():152416. PubMed ID: 38368730
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, Gruben D, Kwok K, Wang C, Hsu MA, Maniccia A.
    RMD Open; 2020 Feb 15; 6(1):. PubMed ID: 32396519
    [Abstract] [Full Text] [Related]

  • 16. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A.
    J Manag Care Spec Pharm; 2019 Nov 15; 25(11):1218-1228. PubMed ID: 31663467
    [Abstract] [Full Text] [Related]

  • 17. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.
    Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM.
    Ann Rheum Dis; 2015 Feb 15; 74(2):326-32. PubMed ID: 25351522
    [Abstract] [Full Text] [Related]

  • 18. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D, Haddad A, Hashoul S, Laor A, Bitterman H, Rosner I, Eder L, Balbir-Gurman A, Mader R, Milman U.
    J Rheumatol; 2013 Jan 15; 40(1):16-22. PubMed ID: 23070992
    [Abstract] [Full Text] [Related]

  • 19. Comorbidity in psoriatic arthritis and rheumatoid arthritis.
    Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L.
    Intern Med J; 2018 Nov 15; 48(11):1360-1368. PubMed ID: 30047189
    [Abstract] [Full Text] [Related]

  • 20. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
    Deyab G, Hokstad I, Whist JE, Smastuen MC, Agewall S, Lyberg T, Ronda N, Mikkelsen K, Hjeltnes G, Hollan I.
    Arthritis Res Ther; 2017 Oct 17; 19(1):232. PubMed ID: 29041979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.